Name

Ashvattha Therapeutics

Legal name

Ashvattha Therapeutics

Website

https://avttx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Ophthalmology Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Precision nanomedicines
• Hydroxyl dendrimer therapeutics
• Ophthalmology drug development
• Neuroinflammation treatments
• Targeted drug delivery

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pre-revenue Clinical Development: Ashvattha Therapeutics is a pre-revenue clinical-stage biopharmaceutical company with no products approved or commercially marketed. Operations are funded by equity financing from venture capital and strategic investors (Series B of $69M in April 2022, Series B Extension of up to $50M in January 2025). No product revenue is currently recognized.
2. Licensing Royalties (Future): Future revenue stream from the exclusive licensing agreement with Huadong Medicine covering China and southeast Asia (Singapore, Malaysia). Huadong advances up to $30M for R&D and $15M for additional preclinical candidates and will pay Ashvattha a royalty of 10% of net sales of licensed products. This stream is contingent on commercial approval of licensed products in the territory.
3. Strategic Partnership / Out-licensing (Future): Management has indicated openness to potential partnership or commercialization transactions for migaldendranib in major markets, leveraging the post-Phase 2 FDA alignment on pivotal trial design. Future revenue could include upfront payments, development milestones, and royalties from global pharma partners.

Go-to-market motion3 records

Core offering

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company developing precision nanomedicines based on its proprietary Hydroxyl Dendrimer (HD) platform, which targets ophthalmology, neurology and inflammatory disease indications. Its lead clinical candidate Migaldendranib (MGB) is a subcutaneous anti-VEGF nanomedicine for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), while OP-101 targets hyperinflammation and [18F]OP-801 is a PET imaging agent for neuroinflammation. The company is pre-revenue and funded by venture capital, with a regional licensing partnership with Huadong Medicine covering Asia.

Product overview

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company whose offering is structured as a single core platform technology — the Hydroxyl Dendrimer (HD) Platform — plus a portfolio of clinical and preclinical module-style candidates built on top of it. The HD platform enables targeted, intracellular precision nanomedicines that traverse tissue barriers (including the blood-retinal barrier and blood-brain barrier) and selectively accumulate in activated/reactive inflammatory cells. Built on this platform are the lead clinical-stage candidate Migaldendranib (MGB, also referenced as D-4517.2 in earlier development) for ophthalmology (DME/nAMD); OP-101 (developed through subsidiary Orpheris) for hyperinflammation including severe COVID-19; the companion diagnostic PET tracer [18F]OP-801 (with the broader OP-801 imaging program) for neuroinflammation imaging; and the preclinical SPECT tracer 111In-D6-B483 for brain tumor imaging. The platform also extends into tissue-targeted variants — hepatocyte-targeted hydroxyl dendrimers (htHD) for liver diseases and bone-targeted hydroxyl dendrimers (btHD) for arthritis/bone disorders — making the portfolio a unified platform-plus-modules architecture in which each named product is a differentiated HD-conjugate or HD-imaging agent derived from the same underlying hydroxyl dendrimer chemistry exclusively licensed from Johns Hopkins University.

Differentiator

Problem solved

Functional benefit

Brands

• OcuPair: A novel dendrimer-hyaluronic acid hydrogel sealant for temporary corneal wound stabilization, referenced as an Ashvattha research program at ARVO 2020.

Products and services

• Migaldendranib (MGB) First-in-class clinical-stage subcutaneous nanomedicine (hydroxyl dendrimer conjugated to a VEGFR/PDGFR tyrosine kinase inhibitor) in Phase 2 development for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). It crosses the blood-retinal barrier in regions of inflammation and selectively normalizes VEGF expression in activated macrophages, microglia, and hypoxic retinal pigment epithelial cells, with demonstrated 78.6% reduction in supplemental anti-VEGF injections in DME and 83.4% reduction in nAMD in a 40-week Phase 2 study, designed for once-monthly at-home self-administration via autoinjector.
• OP-101 Clinical-stage hydroxyl dendrimer therapeutic (HDT) created by conjugation of N-acetyl cysteine (NAC) to the hydroxyl dendrimer, selectively targeting reactive macrophages and microglia to shut down multiple hyperinflammation pathways (NFkB, JAK/STAT/MAPK) in conditions including severe COVID-19 and other viral/bacterial hyperinflammation. Developed initially through wholly-owned subsidiary Orpheris; Phase 2a PRANA study showed reduced risk of mechanical ventilation or death (18% vs 71% for placebo) and attenuated neuronal injury markers.
• [18F]OP-801 PET Imaging Agent Clinical-stage hydroxyl dendrimer-based PET imaging agent (radiolabeled with fluorine-18) developed as a companion diagnostic and pharmacodynamic biomarker for HD therapeutics. It crosses the blood-brain barrier in regions of neuroinflammation and is selectively (>95%) taken up by reactive microglia/macrophages in neurodegenerative diseases including ALS, Alzheimer's disease, Parkinson's disease, and multiple sclerosis; in Phase 1/2 study.
• 111In-D6-B483 SPECT Imaging Agent Preclinical hydroxyl dendrimer SPECT tracer for selective imaging of brain tumors and metastases, extending the HD imaging platform into neuro-oncology applications. Preclinical data presented at the 2021 World Molecular Imaging Congress (WMIC).

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Regeneron Pharmaceuticals: Regeneron markets Eylea (aflibercept), the dominant intravitreal anti-VEGF therapy for nAMD and DME and the comparator in Ashvattha's Phase 2 trial; defines the standard of care migaldendranib must displace.
• Genentech (Roche): Genentech/Roche markets Lucentis (ranibizumab) and Vabysmo (faricimab), the latter a bispecific anti-VEGF/Ang-2 approved for nAMD and DME that materially raises the competitive bar for subcutaneous entrants.

Direct peers

• Ocular Therapeutix: Ocular Therapeutix develops sustained-release intravitreal therapies for retinal diseases including DME and wet AMD, with comparable clinical-stage ophthalmology pipeline targeting reduced treatment burden.
• Adverum Biotechnologies: Adverum develops gene therapies for wet AMD and DME, directly competing with Ashvattha in next-generation ophthalmology therapeutics targeting anti-VEGF pathways with novel delivery modalities.
• REGENXBIO: REGENXBIO develops AAV gene therapies (e.g., ABTICIPARVOVEC) for wet AMD and DME aimed at reducing anti-VEGF injection burden, directly competitive with migaldendranib's value proposition of decreasing treatment frequency in retinal disease.
• Kodiak Sciences: Kodiak Sciences develops antibody biopolymer conjugates for retinal diseases including DME and nAMD, making it one of the closest direct comparables to Ashvattha's migaldendranib in the subcutaneous/intravitreal anti-VEGF space with Phase 3-stage assets.

Emerging players

• AsclepiX Therapeutics: AsclepiX Therapeutics is a clinical-stage ophthalmology biotech previously led by new Ashvattha Interim CEO Robert Dempsey, focused on novel peptide therapeutics for retinal diseases; a relevant emerging peer given shared leadership DNA and overlapping ophthalmology focus.
• Graybug Vision: Graybug Vision develops sustained-release microparticle formulations for wet AMD and other ocular diseases, another emerging retinal-disease biotech pursuing reduced injection frequency with novel delivery technology.
• TearClear: TearClear is an ophthalmology startup previously led by Ashvattha's new Interim CEO Robert Dempsey, developing novel ocular drug delivery; a relevant thematic peer given shared leadership and ophthalmology focus.

Others

• Huadong Medicine: Huadong Medicine is Ashvattha's exclusive Asia licensee and lead investor in the 2022 Series B, controlling China and Southeast Asia rights to the HD pipeline and serving as both a strategic partner and a relevant comparator for BD economics in Asian pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ashvattha-therapeutics-inc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ashvattha Therapeutics